Progress in cystic fibrosis and the CF Therapeutics Development Network

Thorax

Volumn 67, Issue 10, 2012, Pages 882-890

  Rowe, Steven M ^a   Borowitz, Drucy S ^b   Burns, Jane L ^c   Clancy, John P ^d   Donaldson, Scott H ^e   Retsch Bogart, George ^e   Sagel, Scott D ^f   Ramsey, Bonnie W ^c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMELUBANT; AMILORIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ASPARTIC ACID; ATALUREN; AZITHROMYCIN; AZLI; AZTREONAM LYSINE; BIOLOGICAL MARKER; CHLORIDE CHANNEL; CIPROFLOXACIN; COBIPROSTONE; CORTICOSTEROID; DENUFOSOL; DORNASE ALFA; GAMMA1B INTERFERON; GLYCINE; IBUPROFEN; IVACAFTOR; LANCOVUTIDE; LEVOFLOXACIN; LUMACAFTOR; MANNITOL; PANCRELIPASE; PERTZYE; PLACEBO; SODIUM CHLORIDE; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL RESEARCH; DRUG MEGADOSE; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEALTH PROGRAM; HUMAN; LUNG DISEASE; LUNG FIBROSIS; MONOTHERAPY; NONHUMAN; NUTRITIONAL SUPPORT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84866137956     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202550     Document Type: Article

References (126)

1. US Food and Drug Administration. FDA definition 'orphan disease'. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/ HowtoapplyforOrphanProductDesignation/DefinitionofDiseasePrevalence/default.htm (accessed 23 Aug 2012)
2. Pattishall EN. Negative clinical trials in cystic fibrosis research. Pediatrics 1990;85:277-81. (Pubitemid 20064106)
3. Goss CH, Mayer-Hamblett N, Williams J, et al. The cystic fibrosis foundation therapeutics development network: a national effort by the cystic fibrosis foundation to build a clinical trials network. Child Health Care 2008;37:5-20. (Pubitemid 351451040)
4. Goss CH, Mayer-Hamblett N, Kronmal RA, et al. The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases. Adv Drug Deliv Rev 2002;54:1505-28. (Pubitemid 35375773)
5. Marshall BC, Penland CM, Hazle L, et al. Cystic fibrosis foundation: achieving the mission. Respir Care 2009;54:788-95; discussion 95.
6. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-72.
7. Emond MJ, Louie T, Emerson J, et al. Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat Genet 2012;44:886-9.
8. Mayer-Hamblett N, Aitken ML, Accurso FJ, et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007;175:822-8. (Pubitemid 46631794)
9. Mayer-Hamblett N, Kronmal RA. Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial setting. Contemp Clin Trials 2005;26:2-16. (Pubitemid 40693592)
10. Quon BS, Goss CH. A story of success: continuous quality improvement in cystic fibrosis care in the USA. Thorax 2011;66:1106-8.
11. Clancy JP, Jain M. Personalized medicine in cystic fibrosis: dawning of a new era. Am J Respir Crit Care Med 2012.
12. Sloane PA, Rowe SM. Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis. Curr Opin Pulm Med 2010;16:591-7.
13. Davis PB, Yasothan U, Kirkpatrick P. Ivacaftor. Nat Rev Drug Discov 2012;11:349-50.
14. Corbyn Z. Promising new era dawns for cystic fibrosis treatment. Lancet 2012;379:1475-6.
15. Kaiser J. Personalized medicine. New cystic fibrosis drug offers hope, at a price. Science 2012;335:645.
16. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001. (Pubitemid 40638370)
17. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010;363:1991-2003.
18. Aherns R, Rodriguez S, Yen K, et al. VX-770 in subjects 6 to 11 years with cystic fibrosis and the G551D-CFTR mutation. Ped Pulm Suppl 2011;46:A198.
19. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012. Published Online First: 1 March 2012. doi: 10.1378/chest.11-2672
20. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2011;67:12-18.
21. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Nat Acad Sci U S A 2011;108:18843-8.
22. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 2009;106:18825-30.
23. Wang F, Zeltwanger S, Hu S, et al. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels. J Physiol 2000;524(Pt 3):637-48. (Pubitemid 30303615)
24. Bedwell DM, Kaenjak A, Benos DJ, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997;3:1280-4. (Pubitemid 27508832)
25. Clancy JP, Rowe SM, Bebok Z, et al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol 2007;37:57-66. (Pubitemid 46999537)
26. Clancy JP, Bebok Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001;163:1683-92. (Pubitemid 32578776)
27. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003;349:1433-41. (Pubitemid 37211058)
28. Sermet-Gaudelus I, Renouil M, Fajac A, et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med 2007;5:5-14.
29. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447:87-91. (Pubitemid 46685839)
30. Du M, Liu X, Welch EM, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A 2008;105:2064-9. (Pubitemid 351439465)
31. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008;372:719-27.
32. Clancy JP, Konstan MW, Rowe SM, et al. A phase II study of PTC124 in CF patients harboring premature stop mutations. Ped Pulmonol Suppl 2006;41(Suppl 29):abstract 269.
33. Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010;182:1262-72.
34. Konstan M, Accurso F, De Boeck K, et al. Results of the phase 3 study of ataluren in nonsense mutation cystic fibrosis (nmCF). J Cyst Fibros 2012;11 (Suppl 1).
35. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998;95:1005-15. (Pubitemid 29019052)
36. Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels [see comments]. Science 1995;269:847-50.
37. Tarran R, Loewen ME, Paradiso AM, et al. Regulation of murine airway surface liquid volume by CFTR and Ca2+-activated Cl- conductances. J Gen Physiol 2002;120:407-18. (Pubitemid 35014737)
38. Tarran R, Button B, Picher M, et al. Normal and cystic fbrosis airway surface liquid homeostasis: the effects of phasic shear stress and viral infections. J Biol Chem 2005;280:35751-9. (Pubitemid 41532768)
39. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40. (Pubitemid 43113028)
40. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-50. (Pubitemid 43113029)
41. Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011;38:1071-80.
42. Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012;185:645-52.
43. Minasian C, Wallis C, Metcalfe C, et al. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax 2010;65:51-6.
44. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-42. (Pubitemid 24276863)
45. Willumsen NJ, Boucher RC. Transcellular sodium transport in cultured cystic fibrosis human nasal epithelium. Am J Physiol 1991;261 (2 Pt 1):C332-41.
46. Knowles M, Gatzy J, Boucher R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 1981;305:1489-95. (Pubitemid 12244203)
47. Knowles MR, Church NL, Waltner WE, et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990;322:1189-94. (Pubitemid 20137850)
48. App EM, King M, Helfesrieder R, et al. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am Rev Respir Dis 1990;141:605-12. (Pubitemid 20109146)
49. Graham A, Hasani A, Alton EW, et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993;6:1243-8. (Pubitemid 23329537)
50. Quijana F, Doran J, Smith R, et al. Safety and pharmacokinetics of a single dose of 552-02 following aerosolized administration to patients with cystic fibrosis. Pediatr Pulmonol 2005;(Suppl 28):A216.
51. Mason SJ, Paradiso AM, Boucher RC. Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium. Br J Pharmacol 1991;103:1649-56.
52. Ahrens RC, Standaert TA, Launspach J, et al. Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr Pulmonol 2002;33:142-50. (Pubitemid 34123691)
53. Zeitlin PL, Boyle MP, Guggino WB, et al. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest 2004;125:143-9. (Pubitemid 38114576)
54. Deterding R, Retsch-Bogart G, Milgram L, et al. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 2005;39:339-48. (Pubitemid 40411534)
55. Deterding RR, Lavange LM, Engels JM, et al. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med 2007;176:362-9. (Pubitemid 47267470)
56. Accurso FJ, Moss RB, Wilmott RW, et al. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med 2011;183:627-34.
57. Ratjen F, Durham T, Navratil T, et al. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros 2012. Published Online First: 8 June 2012. doi: 10.1016/j.jcf.2012.05.003
58. Mogayzel PJ Jr, Flume PA. Update in cystic fibrosis 2010. Am J Respir Crit Care Med 2011;183:1620-4.
59. Cystic Fibrosis Foundation Patient Registry. 2010 Annual Data Report, 2011.
60. Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010;303:1707-15.
61. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-56. (Pubitemid 37430625)
62. Gibson RL, Emerson J, Mayer-Hamblett N, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007;42:610-23. (Pubitemid 47022973)
63. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-9. (Pubitemid 36801771)
64. Treggiari MM, Rosenfeld M, Retsch-Bogart G, et al. Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatr Pulmonol 2007;42:751-6. (Pubitemid 47580800)
65. Mayer-Hamblett N, Kronmal RA, Gibson RL, et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 2012;47:125-34.
66. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011;165:847-56.
67. Francois B, Luyt CE, Dugard A, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med 2012;40:2320-6.
68. Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002;23:5-27. (Pubitemid 34785780)
69. Sagel SD, Chmiel JF, Konstan MW. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc 2007;4:406-17. (Pubitemid 47330878)
70. Nichols D, Chmiel J, Berger M. Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling. Clin Rev Allergy Immunol 2008;34:146-62.
71. Elizur A, Cannon CL, Ferkol TW. Airway inflammation in cystic fibrosis. Chest 2008;133:489-95. (Pubitemid 351272410)
72. Eigen H, Rosenstein BJ, FitzSimmons S, et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995;126:515-23.
73. Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-54.
74. Lands LC, Milner R, Cantin AM, et al. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007;151:249-54. (Pubitemid 47284135)
75. Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. Chest 1999;115:1053-8. (Pubitemid 29193676)
76. Lai HC, FitzSimmons SC, Allen DB, et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 2000;342:851-9. (Pubitemid 30165208)
77. Konstan MW, VanDevanter DR, Rasouliyan L, et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010;45:1167-72.
78. Wenzel RP, Fowler AA III, Edmond MB. Antibiotic prevention of acute exacerbations of COPD. N Engl J Med. [Review] 2012;367:340-7.
79. Ratjen F, Saiman L, Mayer-Hamblett N, et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa. Chest 2012. Published Online First: 17 May 2012. doi:10.1378/chest.12-0628
80. Konstan MW, Doring G, Lands LC, et al. Results of a phase II clinical trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of CF lung disease. Ped Pulmonol Suppl 2005;28(Suppl 7.4):125-6.
81. Chmiel JF, Konstan MW. Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent. Treat Respir Med 2005;4:255-73. (Pubitemid 41252836)
82. Moss RB, Mayer-Hamblett N, Wagener J, et al. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol 2005;39:209-18. (Pubitemid 40460688)
83. Oermann C, Katz M, Wheeler C, et al. A pilot study evaluating the potential use of low-dose methotrexate as an anti-inflammatory for cystic fibrosis lung disease [abstract]. Pediatr Pulmonol Suppl 2007;30:292-3.
84. Kraynack N, Chmiel J, Xue W, et al. Effect of simvastatin on exhaled nitric oxide and inflammatory markers in sputum in patients with cystic fibrosis [abstract]. Pediatr Pulmonol Suppl 2008;31:300.
85. Konstan M, Hilliard K, Bucur C, et al. Effect of pioglitazone on sputum markers of inflammation in cystic fibrosis [abstract]. Pediatr Pulmonol Suppl 2008;31:310.
86. Williams B, Robinette M, Slovis B, et al. Hydroxychloroquine - pilot study of anti-inflammatory effects in cystic fibrosis [abstract]. Pediatr Pulmonol Suppl 2008;31:314.
87. Tirouvanziam R, Lymp J, Thompson V, et al. A multi-center, phase IIB, randomized, placebo-controlled, double-blind study of the effects of N-acetylcysteine (NAC) on redox changes and lung inflammation in cystic fibrosis patients [abstract]. Pediatr Pulmonol Suppl 2011:280-1.
88. Griese M, Hector A, Kappler M, et al. Inhaled glutathione in cystic fibrosis [abstract]. J Cyst Fibros 2012;11:S11.
89. Stallings VA, Stark LJ, Robinson KA, et al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008;108:832-9. (Pubitemid 351602057)
90. Borowitz D, Baker SS, Duffy L, et al. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr 2004;145:322-6. (Pubitemid 39165679)
91. Hendeles L, Hochhaus G, Kazerounian S. Generic and alternative brand-name pharmaceutical equivalents: select with caution. Am J Hosp Pharm 1993;50:323-9. (Pubitemid 23051955)
92. FitzSimmons SC, Burkhart GA, Borowitz D, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997;336:1283-9. (Pubitemid 27187781)
93. FDA. Exocrine pancreatic insufficiency drug products. Fed Regist 2004;69:23410-14.
94. Trapnell BC, Maguiness K, Graff GR, et al. Efficacy and safety of Creon 24 000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros 2009;8:370-7.
95. Wooldridge JL, Heubi JE, Amaro-Galvez R, et al. EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. J Cyst Fibros 2009;8:405-17.
96. Graff GR, Maguiness K, McNamara J, et al. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study. Clin Ther 2010;32:89-103.
97. Trapnell BC, Strausbaugh SD, Woo MS, et al. Efficacy and safety of PANCREAZE (R) for treatment of exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros 2011;10:350-6. Erratum in J Cyst Fibros 2011;10:491-2.
98. Digestive Care. http://www.digestivecare.com/PDFs/ NDA%20022175%20APPROVAL%2017MAY2012-PI&MG.pdf (accessed 23 Aug 2012)
99. Borowitz D, Goss CH, Stevens C, et al. Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. Pancreas 2006;32:258-63.
100. Borowitz D, Goss CH, Limauro S, et al. Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. J Pediatr 2006;149:658-62.
101. Borowitz D, Stevens C, Brettman LR, et al. Liprotamase long-term safety and support of nutritional status in pancreatic-insufficient cystic fibrosis. J Pediatr Gastroenterol Nutr 2012;54:248-57.
102. Borowitz D, Stevens C, Brettman LR, et al. International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. J Cyst Fibros 2011;10:443-52.
103. Wood LG, Fitzgerald DA, Gibson PG, et al. Oxidative stress in cystic fibrosis: dietary and metabolic factors. J Am Coll Nutr 2001;20(2 Suppl):157-65. (Pubitemid 32423606)
104. Cantin AM, White TB, Cross CE, et al. Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003. Free Radic Biol Med 2007;42:15-31. (Pubitemid 44842010)
105. Shamseer L, Adams D, Brown N, et al. Antioxidant micronutrients for lung disease in cystic fibrosis. Cochrane Database Syst Rev 2010;(12):CD007020.
106. Sagel SD, Sontag MK, Anthony MM, et al. Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis. J Cyst Fibros 2011;10:31-6.
107. Mayer-Hamblett N, Ramsey BW, Kronmal RA. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc 2007;4:370-7. (Pubitemid 47330874)
108. Ordonez CL, Henig NR, Mayer-Hamblett N, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003;168:1471-5. (Pubitemid 38037331)
109. Ahrens R, Rodriguez S, Yen K, et al. VX-770 in subjects 6 to 11 years with cystic fibrosis and the G551D CFTR genotype. Pediatr Pulmonol 2011;34(Suppl):283.
110. Solomon GM, Konstan MW, Wilschanski M, et al. An international randomized multicenter comparison of nasal potential difference techniques. Chest 138:919-28.
111. Boyle MP, Diener-West M, Milgram L, et al. A multicenter study of the effect of solution temperature on nasal potential difference measurements. Chest 2003;124:482-9. (Pubitemid 37000123)
112. Standaert TA, Boitano L, Emerson J, et al. Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol 2004;37:385-92. (Pubitemid 38620059)
113. Davis SD, Rosenfeld M, Kerby GS, et al. Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints. Am J Respir Crit Care Med 2010;182:1387-97.
114. Rosenfeld M, Ratjen F, Brumback L, et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA 2012;307:2269-77.
115. Davis SD, Brody AS, Emond MJ, et al. Endpoints for clinical trials in young children with cystic fibrosis. Proc Am Thorac Soc 2007;4:418-30. (Pubitemid 47333916)
116. Davis SD, Fordham LA, Brody AS, et al. Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. Am J Respir Crit Care Med 2007;175:943-50. (Pubitemid 46684705)
117. Brody AS. Computed tomography scanning in cystic fibrosis research trials: practical lessons from three clinical trials in the United States. Proc Am Thorac Soc 2007;4:350-4. (Pubitemid 47330870)
118. Moss RB, Rodman D, Spencer LT, et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004;125:509-21. (Pubitemid 38223630)
119. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009;135:1223-32.
120. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921-8.
121. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 45:1121-34.
122. Quittner AL, Modi AC, Wainwright C, et al. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135:1610-18.
123. Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;183:1510-16.
124. Konstan MW, Geller DE, Minic P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011;46:230-8.
125. Rosenfeld M, Ratjen F, Brumback L, et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial inhaled hypertonic saline in children with CF. JAMA 2012:1-9.
126. Rosenfeld M, Emerson J, McNamara S, et al. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. Pediatr Pulmonol 2010;45:934-44.